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Orphan G protein-coupled receptors (GPCRs) represent a largely untapped resource for
the treatment of a variety of diseases, despite sophisticated advances in drug discovery.
Two promising orphan GPCRs are the endothelin B receptor-like proteins, GPR37
[ET(B)R-LP, Pael-R] and GPR37L1 [ET(B)R-LP-2]. Originally identified through searches
for homologs of endothelin and bombesin receptors, neither GPR37 nor GPR37L1 were
found to bind endothelins or related peptides. Instead, GPR37 was proposed to be
activated by head activator (HA) and both GPR37 and GPR37L1 have been linked
to the neuropeptides prosaposin and prosaptide, although these pairings are yet to
be universally acknowledged. Both orphan GPCRs are widely expressed in the brain,
where GPR37 has received the most attention for its link to Parkinson’s disease and
parkinsonism, while GPR37L1 deletion leads to precocious cerebellar development and
hypertension. In this review, the existing pharmacology and physiology of GPR37 and
GPR37L1 is discussed and the potential therapeutic benefits of targeting these receptors
are explored.
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INTRODUCTION
Gprotein-coupled receptors (GPCRs) are a family of seven transmembrane (TM)-spanning proteins
that transmit responses from the extracellular milieu by binding to a variety of different ligands,
including neurotransmitters, lipids, peptides, protons, odorants, and light. They are considered to
be ideal drug targets because of their propensity to bind and respond to agonists, antagonists and
allostericmodulators, facilitating a plethora of functional outcomes. The rhodopsin or Class A family
of 296 GPCRs (Lagerstrom and Schioth, 2008) remains the largest source of therapeutic targets;
as of 2014, 79 rhodopsin-like GPCRs were the target of FDA-approved drugs and a further 46
were part of ongoing clinical trials (Rask-Andersen et al., 2014). However, a large number of the
rhodopsin-like receptors are considered to be “orphans” as they are yet to be pairedwith their cognate
endogenous ligand. In this review, the discovery, description and possible therapeutic application of
two endothelin B receptor-like peptide family GPCRs, GPR37 and GPR37L1, will be described.
ENDOTHELINS AND THE ENDOTHELIN B RECEPTOR
Endothelin-1 (ET-1) was first discovered in 1988 (Yanagisawa et al., 1988) and remains the
most potent endogenous vasoconstrictor described to date. There are three endothelin isoforms,
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FIGURE 1 | GPR37, GPR37L1, and their closest relatives. (A) Subsection of the b-subgroup of peptide receptors showing the phylogenetic relationship between
GPR37 and GPR37L1 and the endothelin (ETA and ETB) and bombesin (BB1, BB2, and BB3) receptors. Phylogenetic tree adapted from Fredriksson et al. (2003). (B)
Alignment of human GPR37 and GPR37L1 highlighting sequence conservation in the TM regions. Residues with conserved identity are listed above the alignment,
while conserved similarity is indicated for hydrophobic (#), positively charged (+), negatively charged ( ), or unrelated (.) residues. Predicted TM domains are boxed
and labeled and the C-terminal PDZ motif is underlined.
ET-1, ET-2 and ET-3, which are 21-amino acid peptides with
two intra-chain disulfide bonds (Inoue et al., 1989). ET-1 and
ET-2 are equipotent at both the ETA (Arai et al., 1990) and
the ETB (Sakurai et al., 1990) receptors, while ET-3 is selective
for ETB. The ET family is best known for its role in mediating
potent and long acting vasoconstriction; ET-1 is released from
the vascular endothelium and largely acts in a paracrine manner
on smooth muscle ETA receptors (Kohan et al., 2011). ET levels
are controlled by the ETB receptor, which acts as a “clearance”
receptor on the lung endothelium by binding and internalizing
circulating endothelins (Kohan et al., 2011; Mazzuca and Khalil,
2012). Therapeutic applications of ET antagonists include the
treatment of pulmonary artery hypertension,where dual ETA/ETB
antagonists have been used in the clinic since 2002 (Rubin et al.,
2002; Kohan et al., 2011;Mazzuca andKhalil, 2012), while the ETB
agonist IRL1620 may be useful for enhancing chemotherapeutic
delivery and has recently entered phase II clinical trials (Maguire
and Davenport, 2014). In the late 1990s, the cloning of GPR37
and GPR37L1 suggested that the endothelin family of receptors
may have doubled in size (Figure 1A). However, neither receptor
has been found to respond to endothelins or related peptides, nor
have they been linked to vasoconstriction or pulmonary artery
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hypertension. The putative functions of these ETB-like receptors
are outlined below.
DISCOVERY OF GPR37 AND GPR37L1
Identification of GPR37
The orphan GPCR, GPR37, was first described in 1997 by Zeng
et al. (1997), who discovered a 614 amino acid transcript through
expressed sequence tag (EST) analysis of a human hippocampal
library. The receptor was named human endothelin B receptor-
like protein [hET(B)R-LP] after its closest homolog, the ETB
receptor, to which it shared 52% similarity and 26.7% identity.
Analysis of the receptor sequence revealed four potential N-linked
glycosylation sites, all within the unusually long N-terminus, at
Asn36, Asn138, Asn222, and Asn239 (Zeng et al., 1997). At the same
time, Marazziti et al. (1997) identified what they called GPR37
after sequencing random clones generated from a human frontal
lobe library and searching for novel ESTs. They reported that this
new genemapped to chromosome 7q31, contained two exonswith
an intron that interrupted the sequence in TM3 and matched the
bombesin 2 receptor (BB2), BB1 and ETB with 45, 45, and 41%
overall sequence homology, respectively (TM-based homology
showed GPR37 shared the highest identity with the ETB receptor
at 46.4%). As with Zeng et al. (1997), they also noted the length of
the N-terminus (234 amino acids) and identified a putative signal
peptide (Marazziti et al., 1997). Subsequent studies also reported
identification ofGPR37while searching for homologs of either the
bombesin (Donohue et al., 1998), ETB (Valdenaire et al., 1998), or
both endothelin and bombesin families (Leng et al., 1999). The
murine ortholog was localized to chromosome 6 and found to
have 83% identity to humanGPR37 and similar gene organization
(Marazziti et al., 1998).
Identification of GPR37L1
A year after the discovery of GPR37, Valdenaire et al. (1998)
identified both GPR37 and a very highly related novel transcript
encoding what they called ET(B)R-LP-2 (later termed GPR37L1),
as part of a screen for ETB receptor homologs (Figure 1B).
GPR37L1 was identified as a faint band from a human caudate
nucleus library screen that was then purified, sequenced and
used to re-screen the library. The complete clone had an open
reading frame of 1443 base pairs and encoded a 481 amino
acid GPCR with 68% similarity and 48% identity to GPR37.
Sequence analysis revealed only one potential glycosylation
site, Asn105, in the N-terminus and a putative protein kinase
C phosphorylation site at Tyr332 at the beginning of ICL3.
Alignment of GPR37 and GPR37L1 revealed the presence of
a cysteine cluster at the end of what is now recognized as
helix 8, which they postulated could be a site for palmitoylation
(Valdenaire et al., 1998). Subsequently, both GPR37 andGPR37L1
orthologs were cloned from a rat hypothalamic library: a
603 amino acid 7TM receptor homologous to GPR37, named
GPCR/CNS1, and a 481 amino acid GPR37L1, originally named
GPCR/CNS2 (Donohue et al., 1998). The rat receptors shared
42% homology and were highly similar to the human versions
identified by both Valdenaire et al. (1998) and Donohue et al.
(1998).
Expression Patterns of GPR37
and GPR37L1
BothGPR37 andGPR37L1 are very highly expressed in the central
nervous system, with little peripheral expression in humans and
rodents. Northern blot analyses by several groups universally
demonstrated that GPR37 is present in the brain, particularly the
corpus callosum and substantia nigra (Marazziti et al., 1997; Zeng
et al., 1997; Donohue et al., 1998), with some expression in the
spinal cord, placenta, liver, stomach, and testis (Marazziti et al.,
1997, 1998; Zeng et al., 1997; Donohue et al., 1998; Valdenaire
et al., 1998; Leng et al., 1999). Reports of expression in other
peripheral tissues varied, with Marazziti et al. (1997) failing to
detect GPR37 transcript in human kidney, skeletal muscle, heart,
lung or pancreas, while Leng et al. (1999) reported low levels in
rat heart, liver, kidney and lung, and Zeng et al. (1997) detected a
very faint band by Northern blotting in both the human kidney
and pancreas. Within the brain, GPR37 is localized to neurons
including the Purkinje cells of the cerebellum, pyramidal cells
of the hippocampus and granule cells of the dentate gyrus, as
confirmed by in-situ hybridization (Zeng et al., 1997). To date, the
physiological significance of GPR37 has been largely related to its
expression in the brain.
In contrast to the predominantly neuronal distribution of
GPR37, GPR37L1 is expressed exclusively in glial cells within the
brain, with in-situ hybridization revealing greatest intensity of
GPR37L1 within the Bergmann glia of the cerebellum (Valdenaire
et al., 1998). According to Northern blot analysis in human tissue,
GPR37L1 is highly enriched in the cerebellum and throughout the
brain, with no detectable expression in the periphery, including
heart, kidneys, placenta or pancreas (Valdenaire et al., 1998).
This contrasts with rodent Northern blots, where heart, pituitary,
stomach, lung and some liver and kidney transcripts were
identified (Leng et al., 1999). More recent studies, however, have
identified peripheral GPR37L1 expression by either qPCR or
Western blot analysis in human heart explants (Min et al., 2010)
and the gastrointestinal system (Ito et al., 2009), respectively.
Thus, while it is likely that the majority of the physiological
effects of GPR37L1 are linked to its localization in the central
nervous system, it is possible that GPR37L1 also plays a role in
the periphery.
PHARMACOLOGY AND BIOCHEMISTRY
OF GPR37 AND GPR37L1
Potential Pharmacology of GPR37
and GPR37L1
Because of their relative homology to the endothelin and
bombesin receptors, initial efforts to define the pharmacology
of GPR37 and GPR37L1 focused on testing ligands from these
related receptors in radioligand binding and signaling assays.
For example, GPR37 has been screened for binding of [125I]ET-
1 and [125I] ET-3 (Marazziti et al., 1997; Zeng et al., 1997;
Valdenaire et al., 1998), and [125I]bombesin (Marazziti et al., 1997)
without demonstrable specific binding. Heterologous expression
of GPR37 in Xenopus oocytes or HEK293 cells and stimulation
with bombesin, gastrin-releasing peptide, neuromedin B, Bim
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26292, ET-1, ET-2, or ET-3 (Leng et al., 1999) or ET-1, ET-3,
bombesin and NPY (Zeng et al., 1997) failed to generate calcium
currents, or calcium and cAMP signaling, respectively. Similar
experiments were performed at GPR37L1 with identical results.
Valdenaire et al. (1998), for example, stably expressed GPR37L1 in
HEK293 cells and assessed binding to radiolabeled ET-1 and ET-3,
bombesin, CCK-8 and gastrin-releasing peptide, while Donohue
et al. (1998) microinjected GPR37L1 into Xenopus oocytes or
transfected BALB/B1 fibroblasts and examined [125I]-Bn and
[125I]-[DTyr6,bAla11,Phe13,Nle14]Bn-(6-14) binding and agonism
(calcium and inositol phosphates). Thus, while both GPR37 and
GPR37L1 are closely related to the endothelin and bombesin
receptor families, they are unable to bind to the cognate ligands
for these receptors.
Head Activator and Prosaposin:
Deorphanization of GPR37 and GPR37L1?
The first ligand proposed to be the endogenous partner of
GPR37 was HA, an undecapeptide (pGlu-Pro-Pro-Gly-Gly-
Ser-Lys-Val-Ile-Leu-Phe) originally discovered in Hydra and
reported to have a human homolog (Bodenmuller and Schaller,
1981; Rezgaoui et al., 2006). The authors found that 2 nM
treatment of GPR37 transiently- or stably-transfected cells led
to receptor internalization and FRET-based co-localization of
HA and GPR37, although the images presented were not entirely
consistent with conventional patterns of GPCR internalization.
Intriguingly, when HA-mediated calcium stimulation was
measured using a Ga16/aequorin assay, GPR37 expression led
to translation of HA concentration-response curves along the
Y-axis without a change in potency. This unusual pharmacology
was attributed to endogenous GPR37 already present in the
cells, as detected by Western blot, yet the authors note that they
failed to detect GPR37 transcript by Northern blot (Rezgaoui
et al., 2006), which would ordinarily suggest that the antibody
used for blotting was not specific. Similarly, HA was reported
by Gandia et al. (2013) to stimulate GPR37 internalization,
calcium-mediated nuclear factor of activated T-cells reporter
gene transcription and inhibition of cAMP accumulation.
Interestingly, calcium and cAMP responses were also augmented
(again with an apparent translation along the Y-axis) in a GPR37
deletion mutant, GPR37563–568, which lacked a 6-Cysteine
motif in the C-terminus shown to contribute to the intracellular
retention of GPR37, although the concentration-response curves
shown did not include concentrations at which HA had no
effect on signal transduction, complicating the interpretation of
these findings (Gandia et al., 2013). These studies contrast with
that of Dunham et al. (2009), who attempted to replicate the
finding that HA was a ligand for GPR37 but found no evidence
of HA-mediated internalization, ERK1/2 phosphorylation or
cAMP stimulation. HA was also included in a larger screen of
all remaining orphan GPCRs but did not register as a “hit” for
any GPCR tested (Southern et al., 2013). Finally, perhaps the
most damning evidence against HA as the endogenous ligand for
GPR37 is the fact that it has not been found in the human genome
(Davenport et al., 2013). Thus, it appears that HA is unlikely
to be an agonist at GPR37 and is certainly not its endogenous
ligand.
More recently, GPR37 and GPR37L1 were simultaneously
paired with the endogenous protein prosaposin and its active
peptide fragment, prosaptide (the synthetic analog is called
TX14A; Meyer et al., 2013). In this study, a series of known
neuropeptides was screened against GPR37 and GPR37L1 and
TX14A was found to induce internalization of both receptors.
Biotinylated TX14A was able to immunoprecipitate both GPR37
and GPR37L1, but not their closest relative, the ETB receptor,
or other controls. Based upon ERK1/2 phosphorylation, [35S]-
GTPgS accumulation and inhibition of forskolin-stimulated
cAMP in HEK293T cells co-expressing each receptor, it was
concluded that GPR37 andGPR37L1wereGai-coupled receptors,
consistent with the previously reported role of both TX14A
and prosaposin in the brain (Hiraiwa et al., 1997; Campana
et al., 1998; Misasi et al., 1998). To confirm activity against
the endogenous receptors, the authors turned to primary
cortical astrocytes and down-regulated the expression of the
receptors using siRNA. TX14A was shown to induce ERK1/2
phosphorylation in a GPR37-dependent manner, while either
GPR37 or GPR37L1 deletion was sufficient to prevent TX14A-
mediated neuroprotection. Because the endogenous source
of TX14A is the neuroprotective protein, prosaposin, the
experiments were repeated using recombinant prosaposin and
the same effects were observed (Meyer et al., 2013). Thus, the
authors concluded that prosaposin is the endogenous ligand for
both GPR37 and GPR37L1.
Again, the claim that prosaposin and prosaptide are
endogenous ligands for GPR37 and GPR37L1 is not without some
controversy and is yet to be ratified by the International Union
of Basic and Clinical Pharmacology (IUPHAR) Nomenclature
Committee. First, the concentration of prosaposin or TX14A
required for agonism is 100 nM, much higher than traditionally
associated with peptide/GPCR interactions (e.g., ET-1 binds
to the ETA and ETB receptors with pKd 9.1–10.5 and 9.2–10.0
affinity, respectively; Alexander et al., 2013). Second, Gai/o-
mediated agonism via [35S]-GTPgS led to only a very small
increase in signal above baseline (approximately 8 and 6% above
unstimulated levels for GPR37 and GPR37L1, respectively), in
stark contrast to the doubling usually seen for Gai/o-coupled
GPCRs in this assay (e.g., methacholine stimulates a 95% increase
above baseline at the M2 muscarinic receptor; Mistry et al.,
2011), while both propionate and 4-CMTB stimulate >100%
Gai/o-[35S]-GTPgS incorporation via the free fatty acid 2 receptor
(Smith et al., 2011). Sub-optimal conditions for the [35S]-GTPgS
assay, which is sensitive to concentration of GDP in a receptor-
dependent manner (Mistry et al., 2011), are unlikely to explain
the small signal window as TX14A-mediated cAMP inhibition
was also only 10–15%. An alternative possibility is that both
receptors are highly constitutively active or that there is saturating
endogenous prosaposin already present in the media, leading to
the assay maximum already being reached; normalization of the
data precluded assessment of such activity from the presented
figures. Third, like HA, TX14A was also included in the MRC
Technologies b-arrestin-based orphan GPCR screen but was not
detected as a ligand at either GPR37 or GPR37L1 (Southern et al.,
2013), although it should be noted that Meyer et al. (2013) did
not specifically investigate b-arrestin signaling with these ligands.
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Finally, in the siRNA knockdown experiments using primary
cortical astrocytes, it is unclear how GPR37L1 siRNA was able
to block neuroprotection by TX14A or prosaposin as Western
blot analysis of whole brain and primary astrocytes suggest that
the receptor is markedly downregulated in culture (Meyer et al.,
2013). Thus, a number of questions remain regarding the pairing
of prosaposin with GPR37 and GPR37L1.
While direct agonism remains to be independently
demonstrated for either receptor, it seems likely that prosaposin
and TX14A have some influence on GPR37 subcellular
localization, although the evidence itself is contradictory. For
example, Lundius et al. (2014) created stable GPR37-turboGFP-
expressing catecholaminergic N2a cells and demonstrated by
fluorescence correlation spectroscopy that GPR37 is co-localized
with TX14A and GM1 gangliosides in lipid rafts. Interestingly,
immunoabsorption of extracellular prosaposin reduced GPR37
cell-surface expression (Lundius et al., 2014), an effect that is
opposite to what would be predicted for depletion of an agonist
(receptor upregulation) and in contrast to the ligand-mediated
internalization first reported (Meyer et al., 2013). Further study
is clearly required to understand the complex interplay between
prosaposin and GPR37.
Cell Surface Expression, Cytotoxicity, and
a PDZ Motif at the C-Terminus of GPR37
Since it was first discovered, an ongoing issue with studying
GPR37 has been its poor cell surface expression and cytotoxicity
in heterologous expression systems. For example, C-terminally
tagged GPR37 transient or stable expression in COS-7
and HEK293 cells, respectively, resulted in predominantly
intracellular localization of the receptor (Zeng et al., 1997) and
associated cell death (Imai et al., 2001). Because GPR37 has been
linked to Parkinson’s disease (see below), efforts have focused
on enhancing GPR37 cell surface levels so that the receptor is
amenable to study. One approach has been to rescue expression
through the use of a chemical chaperone, 4-phenylbutyrate (4-
PBA; Kubota et al., 2006). Known to restore cell surface expression
of the cystic fibrosis TM conductance regulator (CFTR) mutant,
F508, 4-PBA was shown to increase cell surface staining and
reduce the concomitant cytotoxicity that resulted from stable
integration of GPR37 in SH-SY5Y neuroblastoma cells (Kubota
et al., 2006). An alternative approach was adopted by Randy
Hall’s group, who hypothesized that cell surface expression
could be rescued by truncation of the long, unstructured GPR37
N-terminus (Dunham et al., 2009), as had been shown for other
GPCRs (Dunham and Hall, 2009). Indeed, cell surface expression
was restored by deletion of the entire N-terminus, as measured by
luminometry and flow cytometry against an N-terminal FLAG
tag, with at least the first 210 residues requiring deletion for rescue
to occur (Dunham et al., 2009). More recently, Gandia et al.
(2013) demonstrated that the region responsible for intracellular
retention of GPR37 was a 6-Cysteine motif in the C-terminus
(Cys563–Cys568) by generating multiple truncation or deletion
mutants. An alternative strategy to genetic manipulation for
increasing cell surface expression of GPCRs is heterodimerization
(Dunham and Hall, 2009; Smith and Milligan, 2010), which was
employed by Dunham et al. (2009), who found that both the
dopamine D2 and adenosine A2A receptors enhanced GPR37
trafficking. Furthermore, co-expression of GPR37 and D2 was
associated with enhanced D2 ligand affinity in [3H]-spiperone
competition binding assays (the 210 GPR37 construct was
used because of its more favorable expression profile), although
this altered affinity did not translate into changes in D2-Gao
fusion protein [35S]-GTPgS signaling nor D2 receptor trafficking
(Dunham et al., 2009).
GPR37 and GPR37L1 both contain PDZ binding motifs at the
end of their C-terminus, raising the possibility that cell surface
expression could be enhanced by direct interactions at this site.
Thus, Hall’s team also probed for novel binding partners of GPR37
by using its PDZ domain-containing C-terminus as bait, which
led to the discovery that GPR37, and later GPR37L1 (Dutta et al.,
2014), interact with the atypical PDZ scaffold protein, syntenin-
1 (Dunham et al., 2009). A subsequent yeast 2-hybrid screen by
Dutta et al. (2014) found that both GPR37 and GPR37L1 interact
with the scaffold/adaptor protein PICK1 (protein interacting with
C-kinase) and that this interaction is specific to the C-terminal
PDZ motif in GPR37 and the PDZ domain in PICK1. Both
receptors also bound to GRIP4/5 (Dutta et al., 2014). In contrast
to the effects on GPR37 expression observed with syntenin-1
(Dunham et al., 2009), co-expression of PICK1 and GPR37 led
to a reduction in GPR37 expression levels and a concomitant
reduction in GPR37-mediated cell death (Dutta et al., 2014).
Finally, GPR37 has been shown to interact specifically with
multi-PDZ domain protein 1 (MUPP1) via its eleventh PDZ
domain to form a scaffold with contactin-associated protein-
like 2 (CASPR2), which has been linked to autism spectrum
disorders (see later; Tanabe et al., 2015). Using mouse brain
homogenates, the authors demonstrated that a GST-CASPR2 C-
terminal fusion protein pulled-down both MUPP1 and GPR37
(as well as GABAB2), while the GST-GPR37 C-terminus, but not a
GST-GPR37 fusion lacking its PDZ domain, was able to pull down
bothMUPP1 andCASPR2 (Tanabe et al., 2015). The physiological
significance of any of these PDZ motif-mediated interactions
remains to be determined, although there is some evidence that
disruption of the GPR37-MUPP1-CASPR2 interaction may be
linked to autism spectrum disorders (see later).
POTENTIAL ROLES OF GPR37 IN HEALTH
AND DISEASE
GPR37 Neurotoxicity and Parkinson’s
Disease
The cytotoxicity seen upon heterologous expression of GPR37
actually provides a clue to a key pathophysiological role of GPR37.
In a seminal 2001 paper by Imai et al. (2001) in Cell, GPR37 was
isolated from a human brain library in a yeast 2-hybrid screen
for novel interacting partners of parkin, and thus named “parkin-
associated endothelin receptor-like receptor” (Pael-R). Parkin is
of great therapeutic interest because mutations in this gene are
directly linked to autosomal recessive juvenile parkinsonism (AR-
JP), a form of parkinsonism notable for its absence of Lewy
bodies. Critically, the authors found that insoluble (and therefore
misfolded) GPR37 was increased in patients with AR-JP, linking
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the aggregation of GPR37 to disease pathogenesis (Imai et al.,
2001). GPR37 aggregates were later also found in a variety of
inclusion bodies in a study byMurakami et al. (2004), who probed
the brains from patients with Parkinson’s disease (PD, n = 6),
dementia with Lewy bodies (DLB, n= 3), multiple system atrophy
(MSA, characterized by glial cytoplasmic inclusions, n = 6)
and six control subjects. In this study, GPR37 aggregates were
identified within the Lewy bodies of PD brain sections, residing
predominantly in the core and sometimes the halo region of
the inclusion. DLB tissue also stained positive for GPR37 in the
same pattern, with GPR37 staining coinciding with parkin and
ubiquitin immunoreactivity in both PD and DLB (Murakami
et al., 2004). No GPR37 was detected in patients with MSA. Thus,
GPR37 aggregation appears to be a hallmark of parkinsonism
(AR-JP and PD) and other, although not all, inclusion-related
neurological diseases.
Molecular Mechanism of GPR37-Mediated
Neurotoxicity
Parkin is an E3 ubiquitin-protein ligase that was itself first
identified in a genetic study of patients with AR-JP, where it
was found to be highly expressed in the brain, particularly
the substantia nigra (Kitada et al., 1998). Mutations in
parkin that have been associated with AR-JP specifically
enhance dopaminergic (DA) neuronal cytotoxicity by failing to
appropriately remove aggregated proteins via the proteasome,
causing the protein aggregates to trigger the unfolded protein
response (UPR) to cause cell death (Figure 2). It is specifically
through the loss of E3 ubiquitin ligase activity that parkin
mutations are pathogenic (Imai et al., 2000; Shimura et al.,
2000; Zhang et al., 2000), leading to the accumulation of a
number of substrates including GPR37 (Imai et al., 2001).
Under normal conditions, misfolded GPR37 is bound to the
molecular chaperone, Hsc/Hsp70, which facilitates appropriate
refolding (Imai et al., 2001, 2002). However, during ER stress,
both parkin and another protein, CHIP (carboxyl terminus of
the Hsc70-interacting protein), become upregulated and CHIP
then promotes the dissociation of Hsc/Hsp70 from GPR37 (Imai
et al., 2002). In the absence of Hsc/Hsp70, GPR37 interacts with
parkin via its C-terminus and is subjected to poly-ubiquitination
and proteasomal degradation, resulting in cytoprotection of the
cell (Imai et al., 2001). In contrast, when parkin is unable to meet
increased demand or has been mutated, unfolded GPR37 is not
ubiquitinated and instead triggers the UPR and neuronal death, a
process that can be rescued by re-expression or overexpression of
wild type parkin (Imai et al., 2001; Figure 2). The possibility that
GPR37 misfolding induces macroautophagy was more recently
proposed, although the evidence was largely circumstantial
(Marazziti et al., 2009). Finally, GPR37 has also been reported to
interact with another E3 ubiquitinase, HDR1, to the same end
(Omura et al., 2006). GPR37L1 does not undergo ubiquitination
(Imai et al., 2001) and thus the phenomenon is limited to GPR37.
GPR37 Knockout Mice and Dopaminergic
Neurotoxicity
A largely unresolved issue in the relationship between GPR37
and neurotoxicity is that GPR37 misfolding seems to specifically
contribute to the loss of DA neurons, despite its broader
expression pattern that encompasses non-DA neurons
and oligodendrocytes (Chung et al., 2001). For example,
overexpression of GPR37 in transgenic Drosophila resulted in an
age-dependent degradation of DA neurons, regardless of whether
the promoter used was pan-neuronal or DA-specific (Yang et al.,
2003). Meanwhile, despite displaying normal neuroanatomy and
largely unaltered components of the DA signaling pathway, global
GPR37 knockout (KO) mice have been shown to display subtle
alterations to DA signaling (Marazziti et al., 2004, 2007, 2011). In
a series of different studies with the same mice (with increasing
number of backcrosses over the years), Marazziti et al. (2004)
have found GPR37 KO mice to have significantly decreased
striatal DA and elevated dopamine transporter (DAT) activity
due to increased presynaptic plasma membrane expression in the
striatum (Marazziti et al., 2007; the same mice have also been
shown to display increased anxiety, discussed below in Section
“Major Depressive Disorder, Bipolar Disorder, and Non-Motor
Attributes of Parkinsonism”; Mandillo et al., 2013). Furthermore,
the increased DAT surface trafficking and activity was shown
to be due to loss of intracellular retention by GPR37 binding
(Marazziti et al., 2007), although a separate study failed to see a
specific interaction between GPR37 and DAT (Dunham et al.,
2009). Consistent with the finding that overexpression of GPR37
enhanced the affinity of various ligands at D2 receptors (Dunham
et al., 2009), D2 receptor ligands had reduced affinity in GPR37
KO mice (Marazziti et al., 2007). Thus, while elements of the
nigrostriatal DA pathway appear to be perturbed, the overall
mechanism of these defects remains to be fully understood.
Several behavioral models have been used to explore the
consequences of these subtle changes in DA signaling, with
somewhat contradictory results. An early study found that
GPR37 KO mice had significantly reduced locomotor activity
in the open field test of general locomotion and exploratory
behavior (Marazziti et al., 2004). These GPR37 KO mice were
more sensitive to amphetamine administration than wild type
littermates, indicated by increased activity, but displayed reduced
motor co-ordination in the rotarod test of balance and agility. The
authors noted that although GPR37 KO mice had significantly
lower body weights than their littermates, this was not found
to affect the results (Marazziti et al., 2004). In a subsequent
study, Marazziti et al. (2007) found that GPR37 KO mice actually
had reduced cocaine-stimulated locomotion; this is surprising as
cocaine and amphetamine both act independently to increase
acute extracellular DA concentrations (amphetamine causes
release of DA from nerve terminals while cocaine prevents
DA reuptake). The mice also had altered responsiveness to
induction of catalepsy by either D1 or D2 antagonism, although
no dose-dependence was observed (Marazziti et al., 2007). While
locomotion and both Akt and ERK1/2 striatal signatures were
differentially affected by cocaine and amphetamine, GPR37 KO
mice failed to respond to either stimulus when used as an
incentive in the conditional place preference behavioral test and
did not develop behavioral sensitization over time (Marazziti et al.,
2011). Finally, when measuring pilocarpine-induced tremulous
jawmovement, amousemodel of PD tremor, GPR37KOmice had
significantly reduced tremulous jaw movements when compared
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FIGURE 2 | GPR37 (mis)folding and its role in cell fate. Folding of the GPR37 polypeptide chain is aided by the molecular chaperone, Hsp70. When the receptor
is correctly folded, it is trafficked to the cell surface where it is able to respond to agonist. However, when the receptor is misfolded, parkin and CHIP displace Hsp70
from the GPR37 polypeptide and parkin, an E3 ubiquitin ligase, polyubiquitinates GPR37 to target it for proteasomal degradation. In cases where parkin is mutated,
such as in AR-JP, or in parkin KO mice, misfolded GPR37 cannot be cleared from the cell and thus forms aggregates. This leads to activation of the unfolded protein
response and ER stress, causing cell death. It is thought that GPR37 protein aggregation contributes to the DA neurotoxicity seen in AR-JP patients who have
mutations in parkin.
to wild type mice, suggesting that a GPR37 antagonist could be an
additional therapeutic approach for the treatment of classical PD
tremor (Gandia et al., 2015). It should be noted, however, that the
extent of DA involvement in PD tremor is unclear (Hallett, 2012).
Thus, taken together, the behavioral effects ofGPR37KO resulting
from DA pathway disruption remain to be fully characterized in
the context of PD.
Interaction Between Parkin and GPR37 in Models
of Neurotoxicity
One of the conundrums in the PD field is the mechanistic link
between parkin, AR-JP and PD more generally. While mutations
within parkin clearly cause AR-JP via DA neurotoxicity and
nigrostriatal neuronal loss, how a recessive mutation in parkin
can cause such a profound phenotype is unclear. Furthermore,
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deletion of parkin in mice does not recapitulate the symptoms
seen in AR-JP and instead results in generally healthy animals
that do not display nigrostriatal neurodegeneration over time,
although they do show elevated DA levels and some behavioral
deficits (Goldberg et al., 2003; Itier et al., 2003). For parkinmice to
develop AR-JP-like symptoms, a “second hit” appears necessary,
whether it be an additional genetic modification or chemical
treatment [such as used in the 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) model of neurotoxicity]. Indeed, the
spontaneous quaking viablemutant mouse that displays abnormal
motor activity, tremor, quaking and seizures, is the result of
simultaneous deletion of both parkin and the upstream parkin
co-regulated gene (PACRG; Lockhart et al., 2004). Several studies
have combined parkin deletionwith changes toGPR37 expression
in an attempt to recapitulate AR-JP. For example, adenoviral-
mediated overexpression of GPR37 in the substantia nigra pars
compacta led to neurotoxicity that was exacerbated in parkin
KO mice (Kitao et al., 2007). This phenotype could be rescued
by overexpression of the ER protein-folding chaperone, Orp150,
or by treatment with the DA synthetase inhibitor, AMPT (a
tyrosine hydroxylase blocker), thus linking GPR37 to ER stress
and subsequent DA neuron death (Kitao et al., 2007). Similar
results were observed in GPR37 transgenic mice crossed with
parkin KO mice, which mimic AR-JP by progressively losing
catecholaminergic neurons without the appearance of Lewy
bodies (Wang et al., 2008). Tyrosine hydroxylase, DAT and
vesicular monoamine transporter 2 were all downregulated in
the striatum of these mice, consistent with the loss of DA nerve
termini, while the UPR was chronically activated. Interestingly,
despite the AR-JP-like neurodegenerative phenotype, no overt
behavioral effects were observed in either the open field test or
rotarod (Wang et al., 2008).
GPR37: Neuroprotective or Neurotoxic?
Excess levels of aggregated GPR37 are clearly neurotoxic while
the proposed ligands for GPR37 are known to be neuroprotective,
suggestive of a functional mismatch that is yet to be resolved.
While the neurotoxicity seen upon GPR37 misfolding can be
explained by failure to clear aggregated protein from the ER, it is
harder to reconcile the survival benefits of GPR37 deletion with
agonist-mediated neuroprotection via prosaposin. For example,
GPR37 KO mice are actually resistant to the development of
DA neurodegeneration and a PD-like phenotype in the MPTP
model of PD neurotoxicity (Marazziti et al., 2004). Meanwhile,
in vitro and in vivo treatment with a retro-inverso version of
the prosaposin peptide, prosaptide D5, also protects DA neurons
from the effects of MPTP administration (Liu et al., 2001). How
overexpression and activation of the same receptor achieves the
opposite phenotypic outcome is unknown, but may be related to
the folding of GPR37. In a recent study, Lundius et al. (2013)
examined the effect ofGPR37-GFPoverexpression on cytotoxicity
mediated by three cytotoxic treatments that mimic components
of PD: MPTP (a precursor to MPP+, an inhibitor of complex I
that leads to mitochondrial dysfunction), rotenone (also causes
mitochondrial dysfunction, leads to Lewy body-like aggregates)
and 6-OHDA (forms reactive oxygen species and activates the
UPR). Overall, GPR37 overexpression was neuroprotective and
this was directly related to its increased cell surface expression
(Lundius et al., 2013). Thus, it is possible that prosaposin acts as a
chaperone for GPR37 to ensure correct folding and trafficking of
the receptor, and that once at the cell surface, GPR37 signaling
is itself neuroprotective. However, this theory is untested and
cannot explain the neuroprotection, rather than absence of
neurotoxicity, seen when GPR37 is deleted. Another possibility is
that prosaposin’s neuroprotective effects are entirely independent
of GPR37—an obvious experiment would be to assess the ability
of prosaposin and prosaptide to enhance cell survival in GPR37
KO mice.
Major Depressive Disorder, Bipolar
Disorder, and Non-Motor Attributes
of Parkinsonism
Tomita et al. (2013) identified GPR37 as a differentially expressed
gene in the brains ofmajor depressive disorder (n= 9) and bipolar
disorder patients (n = 6) when compared to controls (n = 7).
Samples of mRNA were taken for microarray analysis from the
dorsolateral prefrontal cortex and anterior cingulate, regions of
the brain linked to hedonism, impulse control, memory, learning,
and depression. Their global analysis revealed that genes linked to
cAMP signaling were increased in bipolar disorder but decreased
in major depressive disorder (Tomita et al., 2013). Furthermore,
the transcript levels of two orphan GPCRs, GPR37 and GPRC5B,
matched these expression patterns in each disease. Dysregulation
of GPR37 was confirmed by both qPCR and in-situ hybridization
using cortical slices from a separate cohort of major depressive
disorder and bipolar disorder patients. In contrast, a more recent
transcriptome study failed to detect any GPR37 expression in
the post-mortem brains of bipolar disordered patients (Cruceanu
et al., 2015). Thus, while GPR37 may be downregulated in major
depressive disorder, more studies are required to both confirm
this result and determine the effect of bipolar disorder on GPR37
expression.
The potential interaction between GPR37 expression and
affective disorders is also relevant to PD, as PD patients often
experience non-motor symptoms involvingmood, sleep, memory
and learning and sensorimotor disturbances, as well as olfactory
and gastrointestinal perturbations (Chaudhuri et al., 2006). To this
end,Mandillo et al. (2013) used their previously described GPR37
KO mice to investigate non-motor behavioral effects of receptor
deletion. Gender differences were also explored because although
males have a higher prevalence of PD, females experience greater
distress from the non-motor symptoms of PD (Scott et al., 2000;
Negre-Pages et al., 2010). By comparing adult (4–6 months old)
or aged (16–18 months old) wild type and GPR37 KO mice of
both genders, the authors found a series of either gender-specific
or genotype-specific differences, although these were generally
all minor changes. For example, aged female GPR37 KO mice
had significantly increased anxiety and depression-like behaviors,
while olfactory function was marginally improved (Mandillo
et al., 2013). Adult female mice also showed mild change in
gastrointestinal function (increased stool frequency, reduced solid
matter and increased water content), consistent with the noted
expression of the receptor in the gut (Ito et al., 2009) and also
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with the phenotypes of DAT (Walker et al., 2000) and D2 receptor
(Li et al., 2006) KOmice. Both male and female mice had reduced
acoustic startle responses but no significant difference in prepulse
inhibition (Mandillo et al., 2013). The results of this study support
the idea thatGPR37may be responsible for someof the non-motor
symptoms observed in PD, however amore recent study has found
contradictory effects of GPR37 deletion.
Very recently, Lopes et al. (2015) carefully mapped GPR37
expression in the hippocampus and examined the effects
of GPR37 deletion on hippocampal-related behaviors. GPR37
expression was localized predominantly in the extrasynaptic
plasma membrane of dendritic spines and dendritic shafts,
with the remainder largely localized intracellularly (Lopes et al.,
2015), in agreement with Tanabe et al. (2015). While GPR37
deletion had no effect on either short- or long-term plasticity, the
authors examined the effect of adenosine A2A receptor blockade
because that receptor is known to modulate synaptic plasticity
and GPR37 cell surface expression is affected by co-expression
with A2A (Dunham et al., 2009). In general, there was little
difference between untreatedmice and those that received theA2A
antagonist, SCH58261, except for depotentiation after long-term
potentiation, where depotentiation was delayed by SCH58261
in GPR37 KO but not wild type mice (Lopes et al., 2015). A2A
antagonism also specifically modified the response of GPR37 KO
mice in the novel object recognition test of hippocampal-related
working/reference memory. In both instances, the mechanism for
these differences could not be explained. In the earlier study by
Mandillo et al. (2013), older female mice were reported to have
increased anxiety if they lacked GPR37. However, when Lopes
et al. (2015) tested anxiety with either the marble burying test or
elevated plus maze, they found that GPR37 KO mice both buried
less marbles and spent more time in the open arm of the maze,
respectively, indicating that they were actually less anxious than
their wild type littermates. In this instance, treatment with the
A2A receptor antagonist had no effect on wild type anxiety but
reverted the GPR37 KO responses back to that seen for wild type,
i.e., theGPR37KOmice becamemore anxious (Lopes et al., 2015).
This too is a puzzling observation, as A2A KO mice have been
reported to show an anxiolytic, not anxiogenic, phenotype (Wei
et al., 2014). Once again, the behavioral results are contradictory
across GPR37 KOmice models. At the very least, we can conclude
that GPR37 has no effect on working memory but that it may
play a role in anxiety. Discovery of potent GPR37-specific ligands
would undoubtedly help in this regard.
Autism Spectrum Disorders
The gene for GPR37 is found within a locus called AUTS1,
the first region of the human genome to be linked to autism
spectrum disorder (ASD). Several SNPs have been identified
within the coding region of GPR37, with two SNPs segregating
with disease: a 1585–1587 TTC deletion (Del312F, in TM2)
found in a single Japanese patient, and G2324A (R558Q, C-
terminal) from a single Caucasian patient (Fujita-Jimbo et al.,
2012). However, both of these mutations were also detected in
an unaffected relative, suggesting that if either SNP is causal, it
must only be so in the presence of a (presently unidentified)
modifying gene mutation. The authors also noted that a T589M
mutation in the GPR37 C terminus was present in seven affected
men from five different Caucasian families, with only one carrier
identified in the control cohort (Fujita-Jimbo et al., 2012). Each
of the GPR37 mutations were overexpressed in C2C5 cells, where
it was found that both GPR37 Del312F and GPR37 R558Q SNPs
were more highly expressed than wild type GPR37 and that these
cells had altered morphology (Fujita-Jimbo et al., 2012). In a
very recent study, the authors further investigated the effects
of the GPR37 R558Q SNP on the interaction between GPR37
and PDZ binding proteins, MUPP1 and CASPR2 (see earlier;
Tanabe et al., 2015). Interestingly, in GST-CASPR2 C-terminal
pull-down assays, GPR37 R558Qwas less avidly bound toMUPP1
compared to WT GPR37 (only 14% of total GFP-MUPP1).
Furthermore, GPR37 R558Q did not reach the cell surface and
was not co-localized with MUPP1; while co-expression of wild
type GPR37 with MUPP1 did not change receptor distribution,
both were found at the cell surface (Tanabe et al., 2015). Finally,
both MUPP1 and GPR37 were found to co-localize in the
dendrites of hippocampal neuronal cell cultures, as previously
described for GPR37 (Lopes et al., 2015). In contrast, GPR37
R558Q did not traffic to dendrites and although the number of
branching primary dendrites was unaltered between wild type
GPR37 and the GPR37 R558Q-expressing cells, dendrite length
was significantly reduced (Tanabe et al., 2015). Further links
between GPR37 and CASPR2, which has itself been linked to
ASD (Bakkaloglu et al., 2008), were not examined and further
study is clearly required to understand whether GPR37 mutations
contribute to the complex phenotype of ASD.
Testis Development
GPR37 expression was noted to be high in the testes in initial
GPR37 cloning studies (Donohue et al., 1998; Marazziti et al.,
1998), but its role there has been largely unexplored. In a single
recent study, La Sala et al. (2015) investigated the role of GPR37
in gonad differentiation, where they found that both GPR37 and
prosaposin were co-localized in somatic Sertoli cells (SCs) and
that deletion of GPR37 affects germ cell spermatogenesis. GPR37
KOmice are nonetheless still fertile, despite having delayed sperm
cell development, reduced testis weights and lower sperm counts
and sperm motility (La Sala et al., 2015). Gonadal expression
of GPR37 is sexually dimorphic at birth and during postnatal
gonad development, with elevated levels seen inmale gonads only.
Thus, the authors carefully mapped the effect of GPR37 deletion
on sperm cell development from ages P0 (postnatal day 0) to
P29 and found that GPR37 KO mice had altered proportions
of cell types in the germ cell population and that there was a
significant level of apoptosis in seminiferous tubules, from P21
and persisting into adulthood (La Sala et al., 2015). Thus, the
smaller testis size of GPR37KOmicewas attributed to the reduced
number of SCs resulting from impaired proliferation/enhanced
apoptosis. Mechanistically, GPR37 KO mice were found to have
altered levels of androgen receptor and components of the desert
hedgehog (Dhh, the testis-specific member of the hedgehog
mitogens) signaling pathway during pre-pubertal SC maturation.
Specifically, androgen receptor levels were significantly reduced
at P10 and P21, relative to wild type littermates, while Dhh,
patched-1, Smoothened and Gli1 were all significantly elevated
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in GPR37 KOs at P10 and P21, but not in adults (La Sala
et al., 2015). Prosaposin expression was unaltered by GPR37
deletion and GPR37L1 was not found in the testis at any stage of
development or in adulthood (La Sala et al., 2015). Thus, from this
comprehensive study of gonad development in GPR37KOmice, it
can be concluded that GPR37 plays an important role in testicular
development but is not necessary for male fertility.
Other Diseases Associated with GPR37
In addition to the physiological and pathophysiological roles
already outlined, changes in GPR37 expression have been
associated with both cancer and epigenetic regulation. For
example, GPR37mRNA and protein was found to be significantly
downregulated in a panel of tissues from patients with
hepatocellular carcinoma (Liu et al., 2014). Interestingly, GPR37
expression was inversely proportional to the histopathological
grading of the cancer and Kaplan–Meier survival analysis of
patients indicated that those with “low” GPR37 expression
had markedly reduced survival time (n = 37 vs. 20 “high”
GPR37 expressers). Examination of GPR37 siRNA in Huh7 cells
suggested that changes in GPR37 levels altered cell proliferation
and survival (Liu et al., 2014), although this data was less
convincing. At the very least, the evidence suggests that Liu et al.
(2014) have identified a potential biomarker for hepatocarcinoma
severity and survival. In addition to hepatocarcinoma, GPR37
has also been associated with acute myeloid leukemia, where the
gene was found to be hypermethylated in patient samples (Toyota
et al., 2001). Likewise, GPR37 mRNA and protein was found
to be downregulated in a study of the effects of the epigenetic
agent, folic acid, on lymphoblastoid cells (Junaid et al., 2011).
In the latter two studies, the functional significance of GPR37
dysregulation remains to be established.
GPR37L1 PHYSIOLOGY
In contrast to the large number of studies into the physiological
role of GPR37, only two studies have examined the importance of
GPR37L1 to health and disease.
GPR37L1 and Cerebellar Development
The same group that originally cloned GPR37 (Marazziti et al.,
1997) and generated the first GPR37 KO mouse (Marazziti et al.,
2004) has also carefully characterized the effect of GPR37L1 on
brain development and behavior. GPR37L1 KO mice displayed
precocious cerebellumdevelopment thatwas a direct consequence
of premature downregulation of granule neuron precursor
cell proliferation and concomitant premature development and
maturation of Bergmann glia and Purkinje neurons (Marazziti
et al., 2013). The effects of GPR37L1 were linked to dysregulation
of sonic hedgehog (Shh) signaling, which is known to stimulate
proliferation of granule cell precursors and maturation of
Bergmann glia. Western blots of various components of the Shh
pathway revealed altered expression in GPR37L1 KOs during
P5, P10 and P15, key stages of cerebellar development, while
GPR37L1 was found to specifically interact with the Shh receptor,
patched-1, by co-immunoprecipitation from wild type tissue
(Marazziti et al., 2013). Not surprisingly, such marked changes
in cerebellar development translated into phenotypic differences
in behavioral tests—GPR37L1 KO mice had enhanced motor
skills when assessed for rotarod, negative geotaxis, climbing reflex
and wire hanging performance (Marazziti et al., 2013). Although
GPR37L1 deletion caused marked developmental changes in the
cerebellum, the receptor is yet to be linked to the pathogenesis of
disease in the central nervous system, either during development
or adulthood.
GPR37L1: A New Target for Blood Pressure
Control?
GPR37L1 has been linked to the control of blood pressure in
an exciting yet puzzling study of the genetic causes of human
heart failure, where the authors performed microarray analysis
on explants from 12 patients with heart failure, relative to two
reference libraries (Min et al., 2010). A number of different
genes were identified as being differentially regulated according
to the microarray; these plus an additional set of genes identified
by an unreported in silico analysis, which included GPR37L1,
were then further examined. Specifically, GPR37L1 was listed
as being “downregulated” in cardiovascular disease, although no
data was presented to support this claim and p > 0.005 for
the failing vs. non-failing heart comparison of GPR37L1 gene
expression (Min et al., 2010). Adenoviruses were generated to
enable expression of each of the identified genes in isolated
rat neonatal cardiomyocytes and cell growth and viability was
assessed, although this was rather perfunctory. For example,
“apoptosis” was determined by cell morphology, while cellular
hypertrophy was reported as either “increased” or “decreased”
for [3H]-phenylalanine incorporation experiments. Nevertheless,
GPR37L1was reported to reduce cell viability, cause apoptosis and
reduce cellular growth (Min et al., 2010). The most remarkable
observation came from the generation of GPR37L1 KO mice,
which were reported to have an astonishing 62 mmHg increase in
systolic blood pressure when compared to mice that specifically
overexpressed GPR37L1 in the heart (no non-transgenic controls
were used for the comparison). Furthermore, GPR37L1 KO mice
had evidence of significant cardiac hypertrophy as measured by
heart weight to body weight ratios (Min et al., 2010), consistent
with prolonged hypertension. Unfortunately, the authors did not
include any further details that would explain the mechanism
of GPR37L1-mediated blood pressure control, although it is
possible that the extreme difference in systolic blood pressure
could be explained by differing responsiveness to anesthetic
(example traces included in the paper show that GPR37L1
KO mice had far higher heart rate than their cardiac-specific
overexpressing counterparts, which may artificially multiply the
difference between mice). Only one other study has reported the
generation of GPR37L1 KO mice, but blood pressure was not
reported (Marazziti et al., 2013). Meanwhile, a small genome-
wide association study of 424 sudden cardiac death patients with
coronary artery disease reported a SNP with p < 0.0001 near
GPR37L1, however this SNP was not further validated (Arking
et al., 2010). Given the methodological concerns of the original
paper by Min et al. (2010), it is imperative that further studies
explore the role of GPR37L1 in blood pressure homeostasis. If the
phenotype can be confirmed, this work suggests that GPR37L1
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agonists would be useful additional drugs for the treatment of
hypertension.
CONCLUSION
Despite their original discovery as endothelin B receptor-related
proteins, it is evident that neither GPR37 nor GPR37L1 are
receptors for endothelins or endothelin-related ligands. Instead,
GPR37 appears to play a role in DA neurotoxicity and has
been linked to the development of autosomal-recessive juvenile
parkinsonism as well as major depressive and bipolar disorders.
Whether GPR37 is itself neuroprotective or neurotoxic remains
controversial, however, as the reported ligand for GPR37 and
GPR37L1 appears to protect cells from cytotoxic agents while
deletion of the receptor achieves the same outcome. Further
confounding our understanding of the physiological significance
of GPR37 is contradictory behavioral testing results, with some
studies suggesting that GPR37 deletion increases anxiety and
others show the opposite. Meanwhile, only two studies have
investigated the physiological relevance of GPR37L1. Regardless,
GPR37 and GPR37L1 remain promising therapeutic targets
for the treatment of neurodegeneration and hypertension,
respectively, although many additional studies will be necessary
to confirm the mechanisms and relevance of these receptors to
disease.
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